D.E. Shaw & Co
CRXT

D.E. Shaw & Co’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

D.E. Shaw & Co’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,118
Closed -$273K – 5492
2021
Q2 		$273K Buy
+27,118
New +$273K ﹤0.01% 4322

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co's CRXT Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2021, closing a stake of 27,118 shares — an estimated $273K sold.

D.E. Shaw & Co first reported a position in CRXT in Q2 2021 and held it in 1 quarter. The position peaked at $273K in Q2 2021. 12 funds tracked by Wall St. Rank hold CRXT as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,118 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2021, an estimated $273K.
  • D.E. Shaw & Co first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $273K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.